Stealth BioTherapeutics has achieved target enrolment in the Phase III NuPOWER (SPIMD-301) clinical trial of elamipretide to treat primary mitochondrial myopathy (PMM).

The company plans to continue enrolment until the end of the month to allow interested patients to participate in the study.

The placebo-controlled, parallel-group, double-blind, randomised study is designed to evaluate the safety and efficacy of elamipretide in subjects with PMM associated with nuclear DNA mutations (nPMM).

They will receive a single daily dose of elamipretide subcutaneously for 48 weeks.

Change from baseline in distance walked on the six-minute test, which evaluates exercise tolerance, is the primary efficacy outcome of the study.

Secondary outcome measures include triple-timed up-and-go tests and changes from baseline in the time to complete the five times sit-to-stand.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Stealth BioTherapeutics CEO Reenie McCarthy said: “We are thrilled to progress our PMM development efforts toward pivotal data.

“We have partnered closely with the patient community since initiating this programme in 2014, and deeply appreciate the over 350 individuals living with PMM and the many dedicated scientists and clinicians who have participated in and helped design and conduct our clinical trials.

“This important milestone brings us closer to the goal of addressing the unmet need of individuals living with PMM, as we look forward to topline data next year.”

The company is also advancing its lead product candidate, elamipretide, into Phase III clinical trials in dry age-related macular degeneration and Barth syndrome, an ultra-rare cardioskeletal disease.